← Browse by Condition
Medical Condition
pancreatic ductal adenocarcinoma
Total Trials
15
Recruiting Now
15
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for pancreatic ductal adenocarcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — pancreatic ductal adenocarcinoma Clinical Trials
How many clinical trials are currently recruiting for pancreatic ductal adenocarcinoma?
ClinicalMetric currently tracks 15 actively recruiting clinical trials for pancreatic ductal adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 15. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic ductal adenocarcinoma?
pancreatic ductal adenocarcinoma research spans Phase 1 (6 trials), Phase 2 (9 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic ductal adenocarcinoma clinical trial?
Eligibility criteria for pancreatic ductal adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 6
Phase 2 9
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07199764 Phase 2
Recruiting
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Enrollment
100 pts
Location
United States
Sponsor
University of Pennsylvania
NCT06600906
Recruiting
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
Enrollment
70 pts
Location
United States
Sponsor
University of California, San ...
NCT04406831
Recruiting
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Enrollment
200 pts
Location
United States
Sponsor
Nuvance Health
NCT07284277 Phase 1, Phase 2
Recruiting
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Enrollment
30 pts
Location
Spain
Sponsor
Clinica Universidad de Navarra...
NCT07076121 Phase 2, Phase 3
Recruiting
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Enrollment
470 pts
Location
United States, Argen...
Sponsor
Bristol-Myers Squibb
NCT06782412 Phase 2, Phase 3
Recruiting
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Enrollment
109 pts
Location
Belgium
Sponsor
KU Leuven
NCT06467565 Phase 2
Recruiting
NALIRIFOX as Induction Therapy in LAPC
Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06882746 Phase 1
Recruiting
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Enrollment
135 pts
Location
United States
Sponsor
Boehringer Ingelheim
NCT05365893 EARLY_Phase 1
Recruiting
PHL Treatment in Pancreatic Cancer
Enrollment
20 pts
Location
United States
Sponsor
Fox Chase Cancer Center
NCT06445062 Phase 1, Phase 2
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Enrollment
1,130 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
NCT06831136 Phase 2
Recruiting
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
Enrollment
24 pts
Location
United States
Sponsor
The University of Texas Health...
NCT06060405 Phase 2
Recruiting
Durvalumab and Oleclumab in Resectable PDAC
Enrollment
22 pts
Location
Canada
Sponsor
University Health Network, Tor...
NCT06320717
Recruiting
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Enrollment
100 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
NCT04150042 Phase 1
Recruiting
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Enrollment
24 pts
Location
United States
Sponsor
General Oncology, Inc.
NCT06428409 Phase 1, Phase 2
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Enrollment
220 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology